Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
Results of clinical studies in advanced and, recently, also in early breast cancer have shown a clear protective effect of high dose medroxyprogesterone acetate (MPA) on the bone marrow toxicity induced by chemotherapy. The underlying mechanism of this phenomenon is unsettled and in vitro studies have yielded contradictory results. The results of these clinical and in vitro studies are summarized. The myeloprotective effect may have important therapeutical implications.
Wils
J A
JA
Laurentius Hospital, Roermond, The Netherlands.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011897:Random Allocation; D013234:Stem Cells / Q000187:drug effects
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone